Treatment schedule and long-term follow-up of a series of 80 patients with refractory uveitis due to immune-mediated inflammatory diseases (IMID) treated with certolizumab pegol (CZP)
| Conventional immunosuppressant before CZP initiation, n (%) | 60 (75) |
| Ciclosporin | 10 (12.5) |
| Azathioprine | 14 (17.5) |
| Methotrexate | 38 (47.5) |
| Salazopyrin | 28 (35.0) |
| Cyclophosphamide | 1 (1.3) |
| Mycophenolate | 4 (5.0) |
| Leflunomide | 3 (3.8) |
| Pulses of intravenous MP | 4 (5.0) |
| Biological treatment before CZP initiation, n (%) | 52 (63) |
| No. of biological drugs per patient, median (IQR) | 2(1–3) |
| Adalimumab | 48 (60) |
| Infliximab | 32 (40) |
| Etanercept | 7 (8.8) |
| Golimumab | 15 (18.8) |
| Tocilizumab | 5 (6.3) |
| Rituximab | 1 (1.3) |
| Secukinumab | 1 (1.3) |
| Gevokizumab | 1 (1.3) |
| Mean dose of prednisone at CZP initiation (mg/day), mean±SD | 16.9±10.8 |
| CZP regimen | |
| Monotherapy/Combination, n (%) | 39/41 (48.8/51.2) |
| Ciclosporin | 1 (1.3) |
| Azathioprine | 9 (11.3) |
| Methotrexate | 23 (28.8) |
| Salazopyrine | 7 (8.8) |
| Hydroxychloroquine | 1 (1.3) |
| Follow-up time since CZP initiation (months), median (IQR) | 24 (12–36) |
| Optimisation, n (%) | 12 (15) |
| Reason for withdrawal, n (%) | 16 (20) |
| Remission | 3 (3.8) |
| Ocular inefficacy | 4 (5) |
| Extraocular inefficacy | 9 (11.3) |
| Side effects | 0 (0.0) |
MP, methylprednisolone.